



About Novavax

Novavax is a global biotechnology company focused solely on the discovery, development and delivery of innovative vaccines to fight infectious diseases. With a heritage developing vaccines for some of the world's most serious infectious disease threats, the company is advancing a pipeline of vaccine candidates, including COVID-19 variant strains and COVID-19-Influenza Combination vaccines.

Novavax' vaccine platform innovates on a well-understood recombinant protein approach used for decades in vaccines such as hepatitis B and influenza. The company's technology combines immunogenic nanoparticles and proprietary Matrix-M™ adjuvant to boost and broaden the immune response.

Novavax is also collaborating with research institutions, government agencies, foundations and industry to help ensure access and increase uptake of vaccines worldwide.

For more information on Novavax, visit www.novavax.com.